Rice Hall James & Associates’s Medpace MEDP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.9M Sell
53,983
-8,531
-14% -$4.37M 1.44% 22
2025
Q4
$35.1M Sell
62,514
-28,895
-32% -$16.4M 1.93% 9
2025
Q3
$47M Sell
91,409
-11,045
-11% -$4.82M 2.56% 4
2025
Q2
$32.2M Sell
102,454
-673
-0.7% -$202K 1.73% 13
2025
Q1
$31.4M Sell
103,127
-1,356
-1% -$456K 1.85% 11
2024
Q4
$34.7M Sell
104,483
-5,314
-5% -$1.8M 1.91% 10
2024
Q3
$36.7M Sell
109,797
-3,692
-3% -$1.4M 1.98% 9
2024
Q2
$46.7M Sell
113,489
-8,396
-7% -$3.32M 2.8% 5
2024
Q1
$49.3M Sell
121,885
-5,755
-5% -$2.02M 2.81% 5
2023
Q4
$39.1M Sell
127,640
-4,447
-3% -$1.2M 2.27% 8
2023
Q3
$32M Sell
132,087
-9,328
-7% -$2.39M 2.03% 8
2023
Q2
$34M Sell
141,415
-34,437
-20% -$7.15M 1.93% 10
2023
Q1
$33.1M Sell
175,852
-22,399
-11% -$4.63M 1.88% 10
2022
Q4
$42.1M Sell
198,251
-7,671
-4% -$1.53M 2.42% 4
2022
Q3
$32.4M Buy
205,922
+18,777
+10% +$3M 1.88% 9
2022
Q2
$28M Buy
187,145
+3,589
+2% +$520K 1.35% 20
2022
Q1
$30M Buy
183,556
+19,884
+12% +$3.28M 1.2% 24
2021
Q4
$35.6M Sell
163,672
-4,160
-2% -$871K 1.26% 22
2021
Q3
$31.8M Sell
167,832
-2,268
-1% -$414K 1.17% 28
2021
Q2
$30M Sell
170,100
-31,943
-16% -$5.51M 1.07% 28
2021
Q1
$33.1M Buy
202,043
+6,059
+3% +$927K 1.08% 30
2020
Q4
$27.3M Buy
+195,984
New +$24.7M 0.96% 36

Other funds holding MEDP

Rice Hall James & Associates's MEDP Position: Q1 2026 in Review

Rice Hall James & Associates reduced its Medpace (MEDP) stake by 14% in Q1 2026, selling an estimated $4.37M and leaving 53,983 shares worth $25.9M. The position accounts for 1.44% of the portfolio, ranked #22.

Rice Hall James & Associates first reported a position in MEDP in Q4 2020 and has held it in 22 quarters since. The position peaked at $49.3M in Q1 2024. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.

  • Rice Hall James & Associates held 53,983 shares of Medpace worth $25.9M as of Q1 2026.
  • Rice Hall James & Associates sold 8,531 Medpace shares in Q1 2026, an estimated $4.37M.
  • Medpace made up 1.44% of Rice Hall James & Associates's portfolio in Q1 2026, its #22 holding.
  • Rice Hall James & Associates first reported a position in Medpace in Q4 2020 and has held it in 22 quarters since.
  • Rice Hall James & Associates's Medpace position peaked at $49.3M in Q1 2024.
  • 729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.